Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

677
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
677
Tumor Immunotherapy01:27

Tumor Immunotherapy

662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Cancer Vaccines01:30

Cancer Vaccines

514
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
514
What is the Immune System?01:38

What is the Immune System?

116.4K
Overview
116.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-center retrospective cohort study of lung cancer associated with interstitial lung disease: Prognostic factors and molecular profile.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study.

ESMO open·2024
Same author

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients.

Respiratory medicine and research·2023
Same author

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.

ESMO open·2022

Related Experiment Video

Updated: Sep 13, 2025

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.6K

[Autoimmune diseases and immunotherapies].

A Mogenet1, M Duruisseaux2, B Grigoriu3

  • 1Département de pneumologie, allergologie et cancérologie, Aix-Marseille Université, AP-HM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France.

Revue Des Maladies Respiratoires
|July 29, 2025
PubMed
Summary

Immune checkpoint inhibitors treat lung cancer but cause immune-related adverse events. This review synthesizes data on their use in lung cancer patients with autoimmune disease, focusing on efficacy, safety, and treatments.

Keywords:
Auto-immunitéAutoimmunityCancer bronchiqueImmunotherapyImmunothérapieLung cancerPousséeThrustToleranceTolérance

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.8K

Related Experiment Videos

Last Updated: Sep 13, 2025

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.6K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.8K

Area of Science:

  • Oncology
  • Immunology

Context:

  • Immune checkpoint inhibitors (ICIs) are standard lung cancer therapy.
  • ICIs can cause immune-related adverse events (irAEs).
  • Limited data exist on ICI use in patients with pre-existing autoimmune disease (AD).

Purpose:

  • To review and synthesize current literature on ICI efficacy and safety in lung cancer patients with autoimmune disease.
  • To explore the impact of steroids and other therapies on irAEs in this population.

Summary:

  • This article reviews studies examining immune checkpoint inhibitors in lung cancer patients who also have autoimmune disease.
  • It synthesizes information on treatment effectiveness, safety profiles, and management of immune-related adverse events.
  • The review also considers the role of concomitant therapies, such as steroids.

Impact:

  • Provides crucial insights for oncologists and immunologists managing complex patient cases.
  • Informs clinical decision-making regarding the use of immune checkpoint inhibitors in patients with autoimmune disease.
  • Highlights areas for future research in optimizing cancer immunotherapy for vulnerable patient populations.